- Leveragen Inc. and Moonlight Bio have entered a strategic collaboration to develop advanced T cell therapies for hard-to-treat cancers.
- The partnership combines Leveragen’s antibody discovery platform with Moonlight Bio’s expertise in T cell engineering.
Boston-based biotech company Leveragen Inc. has announced a strategic collaboration with Seattle-based Moonlight Bio to develop innovative T cell therapies aimed at treating some of the most challenging cancers. The partnership leverages Leveragen’s Singularity Sapiens Mouse platform, a proprietary tool for generating fully human single-domain antibodies, alongside Moonlight Bio’s advanced cell engineering technologies.
Under the agreement, Leveragen will lead the discovery of fully human single-domain antibodies targeting key therapeutic areas, while Moonlight Bio will oversee preclinical development of the resulting T cell therapies. The collaboration aims to enhance the functionality, persistence, and efficacy of T cell therapies, addressing existing limitations in treating solid tumors.
Weisheng Chen, Founder and CEO of Leveragen, stated, “Through this partnership with Moonlight Bio, we are combining our state-of-the-art antibody discovery platform with their advanced cell engineering capabilities to develop T cell therapies that have the potential to make a meaningful difference for patients.”
Jordan Jarjour, CSO of Moonlight Bio, added, “Leveragen’s Singularity Sapiens Mouse platform is a powerful tool for generating fully human single-domain antibodies with properties that could optimally translate into advanced T cell therapies. We are very excited to collaborate with Leveragen as we explore and create new solutions in this space.”